Capital International, Inc. Bei Gene, Ltd. Transaction History
Capital International, Inc.
- $7.11 Billion
- Q1 2024
A detailed history of Capital International, Inc. transactions in Bei Gene, Ltd. stock. As of the latest transaction made, Capital International, Inc. holds 858,364 shares of BGNE stock, worth $133 Million. This represents 1.89% of its overall portfolio holdings.
Number of Shares
858,364
Previous 809,749
6.0%
Holding current value
$133 Million
Previous $146 Million
8.08%
% of portfolio
1.89%
Previous 2.35%
Shares
22 transactions
Others Institutions Holding BGNE
# of Institutions
214Shares Held
45.1MCall Options Held
76.5KPut Options Held
72.3K-
Baker Bros. Advisors LP New York, NY10.6MShares$1.64 Billion20.93% of portfolio
-
Capital International Investors Los Angeles, CA7.06MShares$1.09 Billion0.23% of portfolio
-
Hhlr Advisors, Ltd. Grand Cayman, E95.18MShares$801 Million17.98% of portfolio
-
Primecap Management CO Pasadena, CA5MShares$774 Million0.59% of portfolio
-
Baillie Gifford & CO3.73MShares$577 Million0.46% of portfolio
About BeiGene, Ltd.
- Ticker BGNE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 103,700,000
- Market Cap $16B
- Description
- BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...